Category Archives: Opioids

MEDX Rockpointe Primary Care 2018 Conferences feature 3 hours of education dedicated to helping clinicians fight the opioid epidemic

In an effort to fight the opioid crisis and to help physicians and other health care providers meet state CME requirements for pain management, Rockpointe is offering 3 hours of CME in three sessions on Developing an Effective Treatment Plan: Opioid and Nonopioid-based Treatment Options for Acute and Chronic Pain Management – Meeting State Pain […]

Oklahoma Requires CME for Prescribers

Many states have taken the cue from the federal government and started their own investigation and research into opioids and the way opioids affect their particular state. Recently, Oklahoma joined the ranks of the states who have not just looked into the situation, but also went so far as to pass legislation to stymy the […]

House Introduces Bill to Require CME for Controlled Substance Prescribing

House of Representatives member Representative Susan W. Brooks recently introduced the ADAPT Act of 2018. The ADAPT Act (Abuse Deterrent and Prescriber Training Act of 2018) is an attempt to require training for prescribers of controlled substances. The bill would amend the Controlled Substances Act to include a requirement for all practitioners who are licensed under […]

Gottlieb Discusses Opioids and Lays Out Vision

On Wednesday, April 4, 2018, Food and Drug Administration (FDA) Commissioner Scott Gottlieb spoke at the National Rx Drug Abuse and Heroin Summit. Gottlieb opened by comparing recent opioid deaths to those that happened at the peak of the AIDS epidemic in 1995. He started off discussing different strategiesthe FDA has pursued to address the challenges presented […]

FDA REMS Blueprint on Opioids Finalized

  On January 30, 2018, the United States Food and Drug Administration (FDA) finalized the “Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain.” The Blueprint includes educational messages for health care providers involved in the treatment and monitoring of patients with pain. It also […]

PhRMA Releases New Policy Proposals

On December 11, 2017, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued statements of support for several policy proposals focused on resolving the opioid crisis. The proposals included: limits on prescribing, a ban on prescribing of Schedule II opioids in an office setting, ongoing prescriber training, and expanded access to addiction treatment options. Along […]

Can CME Help the Opioid Epidemic?

Another day, another story in the news about the opioid epidemic that is transcending America. Local, state, and national elected officials are speaking out about it, as are physicians and patient advocates. Sometimes in life, we are put in a fortunate position to take the lead and to have a life-changing effect on strangers. One […]

Senator Durbin Asks Medical Associations to Endorse Mandatory Opioid CME – AMA Shows Interest

Following last month’s letter to the Pharmaceutical Research and Manufacturers of America (PhRMA), asking the group to “take financial responsibility for the drug industry’s role in curtailing the opioid overdose epidemic,” United States Senator Dick Durbin sent a letter to four physician associations asking them to endorse mandatory CME programs. The letter, which was sent […]

FDA ER-LA REMS Day 2 of the Drug Safety and Risk Management Advisory Committee

  Day Two of the Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) was lively and full of debate and conversation. The day started out with comments from the FDA, followed by presentations by Joanna G. Katzman, MD, MSPH, of the […]

FDA ER-LA REMS Day One of Meeting of the Drug Safety and Risk Management Advisory Committee

  The Food and Drug Administration (FDA) is hosting a two-day long Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to discuss results from assessments of the extended-release and long-acting (ER/LA) Opioid Analgesics REMS. The FDA is seeking comments from the […]

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy